CTOs on the Move

NeuroVision Imaging

www.neurovision.com

 
NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease. The company has developed a novel retinal imaging technology, that is incorporated into a number of clinical trials globally.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NeuroVision Imaging raised $11.2M on 05/02/2018

Similar Companies

Segetis

Segetis, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

A. M. Pappas

A. M. Pappas is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rheonix

Rheonix, Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. As scientific knowledge evolves, so does the need for new diagnostic technology to simplify processes and enhance innovation. Rheonix, through experienced leadership and creative vision, has developed the Encompass platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy to use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and Encompass family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in-between.

Stone Ridge Technology

Stone Ridge Technology is a Bel Air, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axcella Health

Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.